Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence
- PMID: 35597254
- DOI: 10.1016/S2213-8587(22)00134-6
Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence
Conflict of interest statement
OC reports personal fees for giving lectures at congress and travel to congress from Novartis, Recordati, HRA Pharma, and Pfizer; and fees for being co-investigator in clinical research studies funded by Novartis, Recordati, and HRA Pharma. All other authors declare no competing interests.
Comment in
-
Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence - Authors' reply.Lancet Diabetes Endocrinol. 2022 Jun;10(6):385-387. doi: 10.1016/S2213-8587(22)00135-8. Lancet Diabetes Endocrinol. 2022. PMID: 35597255 No abstract available.
Comment on
-
Consensus on diagnosis and management of Cushing's disease: a guideline update.Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20. Lancet Diabetes Endocrinol. 2021. PMID: 34687601 Free PMC article. Review.
Similar articles
-
Osilodrostat (Isturisa) for Cushing's disease.Med Lett Drugs Ther. 2021 Feb 8;63(1617):21-23. Med Lett Drugs Ther. 2021. PMID: 33647005 Review. No abstract available.
-
Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence - Authors' reply.Lancet Diabetes Endocrinol. 2022 Jun;10(6):385-387. doi: 10.1016/S2213-8587(22)00135-8. Lancet Diabetes Endocrinol. 2022. PMID: 35597255 No abstract available.
-
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.Lancet Diabetes Endocrinol. 2020 Sep;8(9):748-761. doi: 10.1016/S2213-8587(20)30240-0. Epub 2020 Jul 27. Lancet Diabetes Endocrinol. 2020. PMID: 32730798 Clinical Trial.
-
COVID-19 infection in a patient with Cushing's disease on osilodrostat treatment.Endokrynol Pol. 2023;74(3):342-343. doi: 10.5603/EP.a2023.0041. Epub 2023 Jun 19. Endokrynol Pol. 2023. PMID: 37335068
-
Osilodrostat for the treatment of Cushing's disease.Expert Opin Pharmacother. 2021 Jun;22(9):1099-1106. doi: 10.1080/14656566.2021.1897106. Epub 2021 Mar 11. Expert Opin Pharmacother. 2021. PMID: 33703978 Review.
Cited by
-
Severe Cushing's syndrome from an ectopic adrenocorticotropic hormone-secreting neuroendocrine tumour treated by osilodrostat.Endocrinol Diabetes Metab Case Rep. 2023 Oct 11;2023(4):23-0076. doi: 10.1530/EDM-23-0076. Print 2023 Oct 1. Endocrinol Diabetes Metab Case Rep. 2023. PMID: 37855644 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources